Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Allogeneic UC-MSCs for Perianal Fistulas in Crohn's Disease
NCT05039411Phase 1Recruiting
- Sponsor
- CryoCord
- Start
- Mar 2022
- Primary completion
- Dec 2026
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PF2020-CELL in perianal fistula, sponsored by CryoCord. Primary endpoint: Incidence of treatment-emergent adverse events at 1.5 years. Started Mar 2022; status: recruiting.
02
Drugs
PF2020-CELL
03
Conditions
perianal fistula
Beyond the preview
Go deeper on NCT05039411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05039411.